دورية أكاديمية
Optimal postoperative surveillance strategies for cancer survivors with gastric neuroendocrine carcinoma based on individual risk: a multicenter real-world cohort study.
| العنوان: | Optimal postoperative surveillance strategies for cancer survivors with gastric neuroendocrine carcinoma based on individual risk: a multicenter real-world cohort study. |
|---|---|
| المؤلفون: | Xu BB; Department of Gastric Surgery.; Department of General Surgery, Fujian Medical University Union Hospital.; Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University.; Fujian Province Minimally Invasive Medical Center., He XY; Division of life Sciences and Medicine, Department of Gastrointestinal Surgery, West district of The First Affiliated Hospital of USTC, University of Science and Technology of China., Zhou YB; Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University., He QL; Department of Gastrointestinal Surgery, The First Affiliated Hospital of Fujian Medical University., Tian YT; Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College., Hao HK; Department of General Surgery, Huashan Hospital, Fudan University., Qiu XT; Department of Gastrointestinal Surgery and Gastrointestinal Surgery Research Institute, the Affiliated Hospital of Putian University., Jiang LX; Department of Gastrointestinal Surgery, Yan Tai Yu Huang Ding Hospital., Zhao G; Department of Gastrointestinal Surgery, Renji Hospital, Shanghai Jiao Tong University., Li Z; Department of General Surgery, Henan Cancer Hospital., Xu YC; Department of Gastrointestinal Surgery, Fujian Medicine University Teaching Hospital, The First Hospital of Putian., Fu WH; Department of General Surgery, Tianjin Medical University General Hospital., Xue FQ; Department of Gastrointestinal Surgery, Provincial Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital., Li SL; Department of Gastrointestinal Surgery, the Second People's Hospital of Liaocheng., Xu ZK; Department of General Surgery, the First Affiliated Hospital of Nanjing Medical University., Zhu ZG; Department of Gastrointestinal Surgery, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine., Li Y; Department of General Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences., Li E; Department of Gastrointestinal Surgery, Meizhou People's Hospital., Chen JP; Department of Gastrointestinal Surgery, Quanzhou First Hospital Affiliated to Fujian Medical University., Li HL; Department of Gastrointestinal Surgery, Second Affiliated Hospital, Nanchang University., Cai LS; Department of General Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, China., Wu D; Department of Gastric Surgery.; Department of General Surgery, Fujian Medical University Union Hospital.; Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University.; Fujian Province Minimally Invasive Medical Center., Li P; Department of Gastric Surgery.; Department of General Surgery, Fujian Medical University Union Hospital.; Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University.; Fujian Province Minimally Invasive Medical Center., Zheng CH; Department of Gastric Surgery.; Department of General Surgery, Fujian Medical University Union Hospital.; Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University.; Fujian Province Minimally Invasive Medical Center., Xie JW; Department of Gastric Surgery.; Department of General Surgery, Fujian Medical University Union Hospital.; Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University.; Fujian Province Minimally Invasive Medical Center., Lu J; Department of Gastric Surgery.; Department of General Surgery, Fujian Medical University Union Hospital.; Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University.; Fujian Province Minimally Invasive Medical Center., Huang CM; Department of Gastric Surgery.; Department of General Surgery, Fujian Medical University Union Hospital.; Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education.; Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University.; Fujian Province Minimally Invasive Medical Center. |
| المصدر: | International journal of surgery (London, England) [Int J Surg] 2023 Jun 01; Vol. 109 (6), pp. 1668-1676. Date of Electronic Publication: 2023 Jun 01. |
| نوع المنشور: | Randomized Controlled Trial; Multicenter Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wolters Kluwer Health, Inc Country of Publication: United States NLM ID: 101228232 Publication Model: Electronic Cited Medium: Internet ISSN: 1743-9159 (Electronic) Linking ISSN: 17439159 NLM ISO Abbreviation: Int J Surg Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : [Philadelphia] : Wolters Kluwer Health, Inc. Original Publication: London : Surgical Associates Ltd., c2004- |
| مواضيع طبية MeSH: | Cancer Survivors* , Carcinoma, Neuroendocrine*/surgery , Carcinoma, Neuroendocrine*/pathology , Stomach Neoplasms*, Humans ; Retrospective Studies ; Cohort Studies ; Neoplasm Recurrence, Local |
| مستخلص: | Background: The best follow-up strategy for cancer survivors after treatment should balance the effectiveness and cost of disease detection while detecting recurrence as early as possible. Due to the low incidence of gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma [G-(MA)NEC], high-level evidence-based follow-up strategies is limited. Currently, there is a lack of consensus among clinical practice guidelines regarding the appropriate follow-up strategies for patients with resectable G-(MA)NEC. Materials and Methods: The study included patients diagnosed with G-(MA)NEC from 21 centers in China. The random forest survival model simulated the monthly probability of recurrence to establish an optimal surveillance schedule maximizing the power of detecting recurrence at each follow-up. The power and cost-effectiveness were compared with the National Comprehensive Cancer Network, European Neuroendocrine Tumor Society, and European Society for Medical Oncology Guidelines. Results: A total of 801 patients with G-(MA)NEC were included. The patients were stratified into four distinct risk groups utilizing the modified TNM staging system. The study cohort comprised 106 (13.2%), 120 (15.0%), 379 (47.3%), and 196 cases (24.5%) for modified groups IIA, IIB, IIIA, and IIIB, respectively. Based on the monthly probability of disease recurrence, the authors established four distinct follow-up strategies for each risk group. The total number of follow-ups 5 years after surgery in the four groups was 12, 12, 13, and 13 times, respectively. The risk-based follow-up strategies demonstrated improved detection efficiency compared to existing clinical guidelines. Further Markov decision-analytic models verified that the risk-based follow-up strategies were better and more cost-effective than the control strategy recommended by the guidelines. Conclusions: This study developed four different monitoring strategies based on individualized risks for patients with G-(MA)NEC, which may improve the detection power at each visit and were more economical, effective. Even though our results are limited by the biases related to the retrospective study design, we believe that, in the absence of a randomized clinical trial, our findings should be considered when recommending follow-up strategies for G-(MA)NEC. (Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.) |
| References: | Maggard MA, O’Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann surg 2004;240:117–122. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76:182–188. van der Veen A, Seesing MFJ, Wijnhoven BPL, et al. Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: a nationwide cohort study. Eur J Surg Oncol 2018;44:1955–62. Lu J, Zhao YJ, Zhou Y, et al. Modified staging system for gastric neuroendocrine carcinoma based on American Joint Committee on Cancer and European Neuroendocrine Tumor Society systems. Br J Surg 2020;107:248–57. Liu DJ, Fu XL, Liu W, et al. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroentero 2017;23:516–524. Wu C, Bao W, Rao Q, et al. Clinicopathological features and prognosis of gastric mixed adenoneuroendocrine carcinoma. Int J Clin Exp Patho 2018;11:1499–509. Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 2016;103:186–194. Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann oncol 2020;31:844–60. Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 2.2021, nccn clinical practice guidelines in oncology. J Nat Comp Cancer Net 2021;19:839–68. Agha R, Abdall-Razak A, Crossley E, et al. STROCSS 2019 guideline: strengthening the reporting of cohort studies in surgery. Int J Surg 2019;72:156–65. Peiris B, Koshy K. A commentary on: “STROCSS 2019 guideline: Strengthening the reporting of cohort studies in surgery” [Int. J. Surg. 72 (2019) 156-165]. Int J Surg 2020;83:255–256. Stekhoven DJ, Bühlmann P. MissForest–non-parametric missing value imputation for mixed-type data. Bioinformatics (Oxford, England) 2012;28:112–118. Zhuang XD, Tian T, Liao LZ, et al. Deep phenotyping and prediction of long-term cardiovascular disease: optimized by machine learning. Can J Cardiol 2022;38:774–82. White C, Nimeh T, Gazelle GS, et al. A decision analysis comparing 3 active surveillance protocols for the treatment of patients with low-risk prostate cancer. Cancer 2019;125:952–62. Zhang Y, Denton BT, Nielsen ME. Comparison of surveillance strategies for low-risk bladder cancer patients. Med Decis Making 2013;33:198–214. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335–1342. Masui T, Ito T, Komoto I, et al. Recent epidemiology of patients with gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NEN) in Japan: a population-based study. BMC Cancer 2020;20:1104. Takayanagi D, Cho H, Machida E, et al. Update on epidemiology, diagnosis, and biomarkers in gastroenteropancreatic neuroendocrine neoplasms. Cancers 2022;14:1119. Lin J, Zhao Y, Zhou Y, et al. Comparison of survival and patterns of recurrence in gastric neuroendocrine carcinoma, mixed adenoneuroendocrine carcinoma, and adenocarcinoma. JAMA Netw Open 2021;4:e2114180. Frizziero M, Wang X, Chakrabarty B, et al. Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres. World J Gastroentero 2019;25:5991–6005. Zhao YJ, Zhuang LP, Liu YY, et al. Comparative study of laparoscopic versus open radical gastrectomy in advanced gastric neuroendocrine carcinoma: analysis from a high-volume institution. Asian J Surg 2020;43:488–96. Morita M, Taguchi K, Kagawa M, et al. Treatment strategies for neuroendocrine carcinoma of the upper digestive tract. Int J Clin Oncol 2020;25:842–50. Chiang CL, Chan SK, Lee SF, et al. Cost-effectiveness of pembrolizumab as a second-line therapy for hepatocellular carcinoma. JAMA Netw Open 2021;4:e2033761. Chiang CL, Chan SK, Lee SF, et al. First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis. Cancers 2021;13:931. Wu B, Li T, Cai J, et al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer 2014;14:984. Hisashige A, Sasako M, Nakajima T. Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1. BMC Cancer 2013;13:443. Huang HL, Leung CY, Saito E, et al. Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. BMC Med 2020;18:257. Xia R, Zeng H, Liu Q, et al. Health-related quality of life and health utility score of patients with gastric cancer: A multi-centre cross-sectional survey in China. Eur J Cancer Care 2020;29:e13283. |
| سلسلة جزيئية: | ClinicalTrials.gov NCT05671393 |
| SCR Disease Name: | Adenocarcinoid tumor |
| تواريخ الأحداث: | Date Created: 20230419 Date Completed: 20230619 Latest Revision: 20230926 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10389463 |
| DOI: | 10.1097/JS9.0000000000000401 |
| PMID: | 37076132 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder كن أول من يترك تعليقا!